# Free triiodothyronine and triglyceride-glucose index interaction on metabolic dysfunction-associated steatotic liver disease risk in euthyroid individuals

**Authors:** Lei Gao, Wenxia Cui, Fenghui Pan, Dinghuang Mu, Weihong Zhou, Yun Hu

PMC · DOI: 10.3389/fendo.2025.1526198 · Frontiers in Endocrinology · 2025-04-24

## TL;DR

This study finds that higher free triiodothyronine and triglyceride-glucose index levels are linked to increased risk of fatty liver disease in people with normal thyroid function.

## Contribution

The study identifies a synergistic interaction between free triiodothyronine and the triglyceride-glucose index in predicting metabolic dysfunction-associated steatotic liver disease.

## Key findings

- Elevated FT3 and TyG index are independently associated with increased MASLD risk.
- The high FT3/high TyG group had significantly higher MASLD risk compared to the low FT3/low TyG group.
- The interaction between FT3 and TyG index showed a significant additive effect on MASLD risk.

## Abstract

The link between thyroid function and insulin resistance and metabolic dysfunction-associated fatty liver disease (MASLD) is becoming increasingly recognized. The primary goal of this study was to investigate the relationship between free triiodothyronine (FT3) levels, the triglyceride-glucose index (TyG) index, and the likelihood of MASLD in euthyroid individuals.

A cross-sectional analysis of 18,298 euthyroid individuals was conducted, comparing 6,144 with MASLD to 12,154 controls. The study evaluated indicators related to clinical, metabolic, and thyroid function. The combined effect of the FT3 and TyG index on the likelihood of MASLD was assessed using logistic regression.

The MASLD group presented with higher male prevalence, older age, and increased rates of hypertension and diabetes. Significant correlations were observed between FT3, TyG, and metabolic parameters. After controlling for potential confounders, FT3 remained significantly associated with increased MASLD risk (adjusted OR = 1.35, 95% CI: 1.23-1.49; P < 0.001). Similarly, the TyG index was independently associated with higher MASLD risk (adjusted OR = 3.99, 95% CI: 3.40-4.68; P < 0.001). The high FT3 (≥ 4.98 pmol/L)/high TyG (≥ 8.55) group exhibited significantly elevated MASLD risk compared to the low FT3/low TyG group (OR = 5.38, 95% CI: 4.62-6.26; P < 0.001).

Elevated FT3 and TyG index are independently associated with an increased risk of MASLD, and they exhibit a significant synergistic additive interaction.

## Linked entities

- **Diseases:** metabolic dysfunction-associated steatotic liver disease (MONDO:0013209), diabetes (MONDO:0005015)

## Full-text entities

- **Diseases:** insulin resistance (MESH:D007333), MASLD (MESH:D005234), steatotic liver disease (MESH:D008107), metabolic dysfunction (MESH:D008659), hypertension (MESH:D006973), diabetes (MESH:D003920)
- **Chemicals:** FT3 (-), triglyceride (MESH:D014280), glucose (MESH:D005947)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12058485/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12058485/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12058485/full.md

---
Source: https://tomesphere.com/paper/PMC12058485